In contrast, EGFR-inhibitors such as cetuximab have not demonstrated clear benefit in HNSCC in the primary setting when compared to standard-of-care platinum-based CRT [32], [33] and are currently approved as an adjunct in recurrent/metastatic patients only [34]. Here, EGFR is linked to head and neck squamous cell carcinoma.